Despite campaign promises to immediately lower prices upon taking office, President Trump’s administration has yet to deliver on this pledge. Democratic lawmakers criticized the lack of concrete policies to address inflation, citing instead a focus on other issues. Economists contend that rapid, broad-based price decreases are both improbable and potentially economically harmful. While some solutions, such as easing housing regulations, exist, they require significant time to implement and may not fully address the complex factors driving current inflation, such as supply chain disruptions and global weather events.
Read More
Drugmakers are set to raise prices on over 250 medications in the US starting January 1st. This news has unsurprisingly sparked widespread outrage and frustration, especially given the timing – just as many are facing economic challenges. The increases, it’s important to note, apply to list prices. These are the prices before rebates and discounts are factored in, meaning pharmacy benefit managers and other intermediaries will likely still receive significant concessions while consumers bear the brunt of the increase.
This raises immediate questions about fairness and accessibility. Many have voiced concerns that those who rely on these medications for chronic or rare conditions will struggle to afford the higher costs, potentially facing life-altering consequences.… Continue reading